GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trevena Inc (OTCPK:TRVN) » Definitions » ROE % Adjusted to Book Value

TRVN (Trevena) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Trevena ROE % Adjusted to Book Value?

Trevena's ROE % for the quarter that ended in Sep. 2024 was 0.00%. Trevena's PB Ratio for the quarter that ended in Sep. 2024 was N/A. Trevena's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was N/A.

Trevena ROE % Adjusted to Book Value Historical Data

The historical data trend for Trevena's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trevena ROE % Adjusted to Book Value Chart

Trevena Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.41 -13.31 -41.05 -188.44 -

Trevena Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -190.35 - - - -

Competitive Comparison of Trevena's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Trevena's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Trevena's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Trevena's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Trevena's ROE % Adjusted to Book Value falls into.


Trevena ROE % Adjusted to Book Value Calculation

Trevena's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-1,014.58% / N/A
=N/A

Trevena's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trevena ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Trevena's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Trevena Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trevena Inc (OTCPK:TRVN) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
IBIO ERNA KTTA CYCC APM LIPO CING BTAX BPTH TOVX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA, USA, 19087
Website
https://www.trevena.com
Trevena Inc is an American biopharmaceutical company focused on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders.
Executives
Mark Corrigan director
Mark Demitrack officer: SVP, Chief Medical Officer 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Robert T Yoder officer: SVP, Chief Business Officer 955 CHESTERBROOK BOULEVARD, SUITE 110, SUITE 200, CHESTERBROOK PA 19087
Carrie L. Bourdow director, officer: President & CEO C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Patricia M. Drake officer: SVP, Chief Commercial Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Barry Shin officer: SVP, CFO C/O TREVENA, INC., 955 CHESTERBROOK BLVD, SUITE 110, CHESTERBROOK PA 19087
Marvin Johnson director C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Moulder Leon O Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Jason Raleigh Nunn director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Scott Braunstein director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Michael R Dougherty director C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Anne M. Phillips director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Scott Applebaum officer: CLCO; SVP, Regulatory Affairs C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
John P. Hamill officer: Int. Prin. Fin. Off. and PAO 4092 NEW HOPE ROAD, FURLONG PA 18925